- Location
Marketing Application
"-
Mark Roush Has Been a Member of The IES for 36 Years
Jul 7, 2015Mark Roush assumes the office of President of the Illuminating Engineering Society of North America (IES), the international leader in lighting education, standards, publications and professional development. Roush succeedes Paul Mercier. ...
Tags: lights, lighting, Illuminating Engineering
-
AVX Has Introduced a New Series of Ultra Broadband Capacitors
Aug 18, 2014AVX has introduced a new series of ultra broadband capacitors designed to address DC blocking from ~16KHz to 40GHz. Exhibiting ultra broadband performance, extremely low insertion loss, and excellent return loss, the new GX0S Series ...
Tags: AVX, Electrical, Electronics
-
GX0S Series Ultra Broadband Capacitors Are Available
Apr 24, 2014GX0S Series Ultra Broadband Capacitors are available with X5R characteristics & exhibit extremely low insertion loss & excellent return loss AVX Corporation, a leading manufacturer of advanced passive components and interconnect ...
Tags: Electrical, Electronics, Capacitor
-
Gilead Sciences Has Received Notice of Compliance From Health Canada
Dec 19, 2013Gilead Sciences has received notice of compliance from Health Canada for its once-daily oral nucleotide analog polymerase inhibitor Sovaldi or sofosbuvir 400mg tablets for the treatment of chronic hepatitis C or CHC infection. Sovaldi is ...
-
AVX Corporation Doubled 0603 Mloc Capacitance
Dec 17, 2013AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has doubled the capacitanceThat property of a system of conductors and dielectrics which permits the storage of electricity when potential difference ...
Tags: Electrical, Electronics
-
FDA Extended Its Review of a Marketing Application for Fusion Protein Alprolix
Dec 5, 2013Biogen Idec announced that the US Food and Drug Administration (FDA) has extended its review of a marketing application for the long-lasting recombinant factor IX Fc fusion protein Alprolix for haemophilia B by three months. The company ...
-
Gentium Announced That Defibrotide Has Been Designated as an Orphan Drug for The Treatment
Nov 19, 2013Italy-based Gentium and Link Healthcare announced that defibrotide has been designated as an orphan drug for the treatment of hepatic veno-occlusive disease (VOD). The sponsor of Defibrotide is Link Healthcare, Gentium's exclusive ...
Tags: Gentium, Orphan Drug
-
National Phase Approvals to Apricus Biosciences's Vitaros
Aug 20, 2013The Irish Medicines Board and the Netherlands' Medicines Evaluations Board have granted national phase approvals to Apricus Biosciences' Vitaros, indicated to treat patients with erectile dysfunction (ED). Vitaros now has four national ...
Tags: Apricus Bio, Medicine
-
Astellas Pharma and Medivation Have Announced The Submission of Application
May 27, 2013Astellas Pharma and Medivation have announced the submission of application for marketing approval of enzalutamide in Japan for the treatment of prostate cancer. The application was filed by Astellas with the Ministry of Health, Labour ...
Tags: Astellas, Marketing Application
-
SPI Subsidiary Sucampo Pharmaceuticals Received Approval in Japan for Amitiza
Dec 5, 2012SPI subsidiary Sucampo Pharmaceuticals has received approval from the Ministry of Health, Labor and Welfare in Japan for Amitiza (lubiprostone), a prescription drug for the treatment of chronic constipation, excluding constipation caused by ...
Tags: amitiza, lubiprostone, treatment of chronic constipation, prostone
-
Genzyme Received a Refuse to File Letter From The US Food and Drug Administration
Aug 27, 2012Genzyme, a Sanofi company, has received a refuse to file letter from the US Food and Drug Administration (FDA) in response to the supplemental Biologics License Application (sBLA) for the approval of Lemtrada (alemtuzumab) as a treatment ...
Tags: Genzyme, Lemtrada marketing, FDA
-
Janssen Research Submitted a Supplemental New Drug Application to FDA for Zytiga
Jun 18, 2012Janssen Research & Development has announced that it has submitted a supplemental New Drug Application to FDA for ZYTIGA(abiraterone acetate). Janssen-Cilag International NV has also sent a type II variation to the European Medicines ...
